Breaking News Instant updates and real-time market news.

MRTX

Mirati Therapeutics

$97.45

-2.65 (-2.65%)

16:49
11/04/19
11/04
16:49
11/04/19
16:49

Mirati Therapeutics reports Q3 EPS ($1.38), consensus ($1.25)

Reports Q3 revenue $988,000, consensus $210,000. Reports cash, cash equivalents, and short-term investments were $454.2M at September 30 compared to $222.8M at December 31, 2018. The company said, "The recent data presented demonstrate that MRTX849 treatment can result in clinical responses at well tolerated doses. We believe that MRTX849 clinical combinations, including the combination of MRTX849 with TNO155 in our collaboration with Novartis, will significantly increase the eligible patient population. We continue to expand and accelerate our KRAS programs and expect to continue expanding our team, including the addition of commercial talent so that we are ready to deliver our novel cancer therapies to the patients most in need."

  • 05

    Nov

MRTX Mirati Therapeutics
$97.45

-2.65 (-2.65%)

10/09/19
SBSH
10/09/19
NO CHANGE
Target $130
SBSH
Buy
Mirati Q4 data could send stock 'meaningfully higher,' says Citi
Citi analyst Yigal Nochomovitz continues to have favorable expectations for Mirati Therapeutics' (MTRX) initial MRTX849 data in Q4 and believes that a response rate in non-small-cell lung carcinoma in line with Amgen's (AMGN) ~50% should drive the stock "meaningfully higher." In addition, given the small sample size, the analyst believes that a slightly lower potential response rate, like in the 35%-40% range, "should not by default be viewed as inferior." He keeps a Buy rating on Mirati shares with a $130 price target.
10/29/19
CANT
10/29/19
NO CHANGE
Target $85
CANT
Overweight
Mirati Therapeutics price target raised to $85 from $81 at Cantor Fitzgerald
Cantor Fitzgerald analyst Varun Kumar raised his price target for Mirati Therapeutics to $85 from $81 saying the company's agent provided the initial proof-of-concept data in non-small cell lung cancer and in colorectal cancer patients with KRAS G12C mutation. This should be seen positively overall for the stock, says Kumar, who reiterates a Neutral rating on Mirati.
10/29/19
HCWC
10/29/19
NO CHANGE
Target $117
HCWC
Buy
Mirati Therapeutics initial MRTX849 data impressive, says H.C. Wainwright
H.C. Wainwright analyst Edward White says Mirati Therapeutics' (MRTX) initial MRTX849 data are impressive and comparable with Amgen's (AMGN) AMG510's results. The analyst continues to estimate MRTX849 sales of $135.5M in 2023, growing to approximately $1.5B in 2027. He keeps a Buy rating on Mirati Therapeutics with a $117 price target.
10/29/19
COWN
10/29/19
NO CHANGE
COWN
Outperform
Mirati Therapeutics data impressive, says Cowen
Cowen analyst Chris Shibutani called the data release from Mirati Therapeutics, "impressive" citing both the response and safety profile. The analyst said the monotherapy response in CRC is an upside surprise and caused him to raised his DCF to $125 from $120. Shibutani reiterated his Outperform rating on Mirati Therapeutics shares.

TODAY'S FREE FLY STORIES

SPT

Sprout Social

20:34
12/12/19
12/12
20:34
12/12/19
20:34
Syndicate
Sprout Social 8.824M share IPO priced at $17.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SCHW

Charles Schwab

$51.08

1.48 (2.98%)

20:16
12/12/19
12/12
20:16
12/12/19
20:16
Upgrade
Charles Schwab rating change  »

Charles Schwab upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$84.00

-2.97 (-3.41%)

20:08
12/12/19
12/12
20:08
12/12/19
20:08
Upgrade
Bluebird Bio rating change  »

Bluebird Bio upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$6.73

-0.97 (-12.60%)

20:07
12/12/19
12/12
20:07
12/12/19
20:07
Syndicate
Aquestive Therapeutics 7M share Secondary priced at $5.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BY

Byline Bancorp

$18.95

0.54 (2.93%)

19:56
12/12/19
12/12
19:56
12/12/19
19:56
Hot Stocks
Byline Bancorp initiates 3c per share cash dividend »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

NXGN

NextGen Healthcare

$16.83

-1.28 (-7.07%)

19:08
12/12/19
12/12
19:08
12/12/19
19:08
Downgrade
NextGen Healthcare rating change at Cantor Fitzgerald »

NextGen Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AMOT

Allied Motion

$46.79

0.81 (1.76%)

18:57
12/12/19
12/12
18:57
12/12/19
18:57
Hot Stocks
Allied Motion CEO sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LILA

Liberty Latin America

$17.56

0.32 (1.86%)

, DISCA

Discovery

$32.36

0.28 (0.87%)

18:54
12/12/19
12/12
18:54
12/12/19
18:54
Hot Stocks
Liberty Latin America says Dr. John Malone retires from board »

Liberty Latin America…

LILA

Liberty Latin America

$17.56

0.32 (1.86%)

DISCA

Discovery

$32.36

0.28 (0.87%)

LGF.A

Lionsgate

$9.99

0.65 (6.96%)

LGF.B

Lionsgate

$9.35

0.7 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOCPY

Hoya Corp.

$0.00

(0.00%)

, TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

18:43
12/12/19
12/12
18:43
12/12/19
18:43
Hot Stocks
Hoya to offer JPY12,900 per share in tender offer for Toshiba unit NuFlare »

Hoya Corporation (HOCPY)…

HOCPY

Hoya Corp.

$0.00

(0.00%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

ADBE

Adobe

$305.76

2.01 (0.66%)

, SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:42
12/12/19
12/12
18:42
12/12/19
18:42
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Adobe…

ADBE

Adobe

$305.76

2.01 (0.66%)

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

DDOG

Datadog

$35.75

0.23 (0.65%)

RIG

Transocean

$5.94

0.28 (4.95%)

TPR

Tapestry

$26.35

0.515 (1.99%)

GTIM

Good Times Restaurants

$1.71

0.14 (8.92%)

ORCL

Oracle

$56.47

0.16 (0.28%)

AVGO

Broadcom

$327.39

7.53 (2.35%)

COST

Costco

$297.50

2.28 (0.77%)

CNC

Centene

$58.52

-0.13 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 23

    Jan

  • 23

    Mar

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:40
12/12/19
12/12
18:40
12/12/19
18:40
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta up 28.5% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHR

Phreesia

$28.67

0.1 (0.35%)

18:38
12/12/19
12/12
18:38
12/12/19
18:38
Syndicate
Phreesia 6.75M share Secondary priced at $26.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:31
12/12/19
12/12
18:31
12/12/19
18:31
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta to resume trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

18:25
12/12/19
12/12
18:25
12/12/19
18:25
Hot Stocks
Adobe CEO: We are not overly concerned with the trade war with China »

Comment from interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:20
12/12/19
12/12
18:20
12/12/19
18:20
Hot Stocks
Sarepta announces FDA approval of VYONDYS 53 injection to treat DMD »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,760.44

11.33 (0.65%)

18:11
12/12/19
12/12
18:11
12/12/19
18:11
Hot Stocks
Amazon orders fourth season of 'The Marvelous Mrs. Maisel' »

Amazon Studios announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHAI

OHA Investment

$1.28

(0.00%)

, PTMN

Portman Ridge Finance

$2.04

(0.00%)

18:10
12/12/19
12/12
18:10
12/12/19
18:10
Hot Stocks
OHA Investment obtains stockholder approval of Portman Ridge deal »

OHA Investment…

OHAI

OHA Investment

$1.28

(0.00%)

PTMN

Portman Ridge Finance

$2.04

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCT

Oncternal Therapeutics

$4.62

0.05 (1.09%)

18:05
12/12/19
12/12
18:05
12/12/19
18:05
Hot Stocks
Oncternal presents interim data from Phase 1b clinical study of cirmtuzumab »

Oncternal Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZN

Horizon Global

$3.49

0.14 (4.18%)

18:03
12/12/19
12/12
18:03
12/12/19
18:03
Hot Stocks
Horizon Global CFO Jamie Pierson steps down »

Horizon Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

18:03
12/12/19
12/12
18:03
12/12/19
18:03
Hot Stocks
Oracle CEO Catz says expects momentum in 2H20 to carry into FY21 »

Says feels "very…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:00
12/12/19
12/12
18:00
12/12/19
18:00
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

17:52
12/12/19
12/12
17:52
12/12/19
17:52
Hot Stocks
Oracle's Ellison says 'we have no plans for having a second CEO' »

Says there won't be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

, EVRC

Evercel, Inc

$0.00

(0.00%)

17:41
12/12/19
12/12
17:41
12/12/19
17:41
Hot Stocks
NewLink Genetics advances over 11% after Evercel discloses rejected offer »

Shares of NewLink…

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

EVRC

Evercel, Inc

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRC

Evercel, Inc

$0.00

(0.00%)

, NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

17:36
12/12/19
12/12
17:36
12/12/19
17:36
Hot Stocks
Evercel announces rejected offer to acquire NewLink Genetics »

Evercel (EVRC) has made…

EVRC

Evercel, Inc

$0.00

(0.00%)

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXRX

Baudax Bio

$6.30

0.225 (3.70%)

17:34
12/12/19
12/12
17:34
12/12/19
17:34
Hot Stocks
Corsair Capital reports 8.77% passive stake in Baudax Bio »

Corsair Capital disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.